Neal J Meropol
Overview
Explore the profile of Neal J Meropol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
9539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, et al.
Contemp Clin Trials Commun
. 2025 Mar;
44:101446.
PMID: 40027276
Background: Discovery and incorporation of predictive and prognostic biomarkers enhance outcomes for patients with cancer. Clinico-genomic datasets, which retrospectively link real-world clinical data to tumor sequencing data, are important resources...
2.
Herbst R, Blumenthal G, Khleif S, Lippman S, Meropol N, Rosati K, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39666955
Public-private partnerships (PPPs) in cancer research have emerged as a pivotal model in the development of strategies to rapidly advance therapeutic innovations. The collaboration between public entities, such as government...
3.
Prindiville S, Mandrekar S, Meropol N, Denicoff A, Grad O, Hautala J, et al.
J Natl Cancer Inst
. 2024 Sep;
117(3):396-401.
PMID: 39325869
The increase in the complexity of cancer clinical trials over the past several decades has led to a dramatic growth in trial cost and operational burden. The extent and frequency...
4.
Singh A, Balogh E, Carlson R, Huizinga M, Malin B, Melamed A, et al.
JCO Oncol Pract
. 2024 Aug;
21(2):128-135.
PMID: 39102623
Electronic health records (EHRs) are a significant advancement over paper records. However, the full potential of EHRs for improving care quality, patient outcomes, surveillance, and research in cancer care is...
5.
Altomare I, Wang X, Kaur M, Guadamuz J, Falk S, Xiao F, et al.
JNCI Cancer Spectr
. 2024 Jul;
8(4).
PMID: 39041606
Background: Expanding access to clinical trials in community settings is a potential approach to addressing disparities in accrual of historically underrepresented populations. However, little is known about the characteristics of...
6.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Breast Cancer Res Treat
. 2024 Jul;
207(2):275-282.
PMID: 38967884
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical...
7.
Kaur M, Frahm F, Lu Y, Ascha M, Guadamuz J, Dotan E, et al.
NEJM Evid
. 2024 May;
3(4):EVIDoa2300236.
PMID: 38771994
Background: Certain populations have been historically underrepresented in clinical trials. Broadening eligibility criteria is one approach to inclusive clinical research and achieving enrollment goals. How broadened trial eligibility criteria affect...
8.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Res Sq
. 2024 May;
PMID: 38746356
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical...
9.
Giantonio B, Catalano P, Meropol N, ODwyer P, Mitchell E, Alberts S, et al.
J Clin Oncol
. 2023 Jul;
41(21):3670-3675.
PMID: 37459754
Purpose: Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer....
10.
Parikh R, Basen-Enquist K, Bradley C, Estrin D, Levy M, Lichtenfeld J, et al.
J Natl Cancer Inst
. 2022 May;
114(10):1338-1339.
PMID: 35640986
Digital health advances have transformed many clinical areas including psychiatric and cardiovascular care. However, digital health innovation is relatively nascent in cancer care, which represents the fastest growing area of...